Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neurocrine Bioscienc (NQ: NBIX )

97.05 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 97.05
Bid (Size) 91.45 (1)
Ask (Size) 102.78 (1)
Prev. Close 97.05
Today's Range 97.05 - 97.05
52wk Range 75.25 - 129.29
Shares Outstanding 94,900,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
3 Growth Stocks That Could Disrupt the Healthcare Industry
These healthcare growth stocks will continue to provide steady and consistent returns, rewarding smart investors over time. 
Via InvestorPlace
Analyst Expectations for Neurocrine Biosciences's Future
 
Via Benzinga

Performance

YTD
-19.18%
-19.18%
1 Month
-5.27%
-5.27%
3 Month
-18.40%
-18.40%
6 Month
-3.50%
-3.50%
1 Year
+3.70%
+3.70%

More News

Read More
Benzinga's Top Ratings Upgrades, Downgrades For March 3, 2023
Via Benzinga
Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
From Sentia Medical Sciences, Inc.
Via Globe NewsWire
Neurocrine Bio Tops Fourth-Quarter Views As Profit Skyrockets
Via Investor's Business Daily
Neurocrine Biosciences Earnings Preview
Via Benzinga
Why Voyager Therapeutics Stock Is Sinking This Week
Via The Motley Fool
Earnings Scheduled For February 6, 2023
Via Benzinga
Five Best And Worst Performing Healthcare Stocks In January 2023
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023
Via Benzinga
Analyst Views Karuna Therapeutics' New Licensing Deal 'As Intriguing'
Via Benzinga
Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
Via MarketBeat
7 A-Rated Stocks to Buy for Less Than $25
Via InvestorPlace
Stock Market Rally Gains Steam As Inflation Cools; Tesla Price Cuts, Big Earnings In Focus: Weekly Review
Via Investor's Business Daily
Voyager Therapeutics (VYGR) Stock Gains 18% on Gene Therapy Deal
Via InvestorPlace
Neurocrine Biosciences, Voyager Therapeutics Collaborate For Neurological-Focused Gene Therapies
Via Benzinga
Have A Look At William Blair's Top Biotech Picks For 2023
Via Benzinga
Dow Jones Giant UnitedHealth Among 5 Resilient Stocks In Sickly Market Rally
Via Investor's Business Daily
Despite Neurocrine's Epilepsy Drug Missing Primary Goal In Pediatric Trial, Analyst Sees Strong Growth
Via Benzinga
How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market
Via Benzinga
Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm
Via Investor's Business Daily
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Heska To $165? Plus BTIG Cuts PT On This Stock By 67%
Via Benzinga
Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
Via MarketBeat
Looking Into Neurocrine Biosciences's Return On Capital Employed
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.